Long-term efficacy data of dupilumab for eosinophilic oesophagitis

Expert Name
Dr Evan S. Dellon

Dupilumab showed maintained patient benefits in an eosinophilic oesophagitis (EoE) population. The 28-week extended treatment period of the randomised, double-blind, placebo-controlled, phase 3 LIBERTY EoE TREET trial showed sustained symptomatic, histologic, and endoscopic benefits of dupilumab. The drug was well tolerated and few severe adverse events were reported. Dupilumab is a human monoclonal antibody inhibiting IL-4 and IL-13 signalling. Part…

1-Minute Summary: Budesonide Orodispersible Tablets Maintain Remission in a Randomized, Placebo-Controlled Trial of Patients With Eosinophilic Esophagitis

Expert Name
Dr A. Straumann, et al.

Eosinophilic oesophagitis (EoE) is a chronic inflammatory disease requiring long-term therapeutic management [1-3]. Currently, swallowed topical corticosteroids (STC) are the first-line medical therapy for active disease [4]. Nonetheless, oesophageal targeting and efficacy of STC are suboptimal. A new formulation of budesonide orodispersible tablet (BOT) showed efficacy in EoE in a 6-week phase 3 trial [5]. The current phase 3, randomised,…

1-Minute Summary: A Network Meta-Analysis of Randomised Controlled Trials on the Treatment of Eosinophilic Esophagitis in Adults and Children

Expert Name
Dr Theodore Rokkas

Rokkas T, et al. A network meta-analysis of randomized controlled trials on the treatment of eosinophilic esophagitis in adults and children. J Clin Gastroenterol 2020; published ahead of print. For eosinophilic esophagitis (EoE), apart from steroids [1], newer therapeutic interventions and relevant randomised controlled trials (RCTs) are available that have not been included in previous meta-analyses [2-6]. Network meta-analysis (NWM)…

Locally active corticosteroid promising in eosinophilic oesophagitis

Orodispersible budesonide delivered specifically to the oesophagus as a tablet was effective in inducing clinical and histological remission in patients with eosinophilic oesophagitis, according to the data from the EOS-2 trial, reported by Prof. Alfredo Lucendo (Tomelloso General Hospital, Spain) [1]. EOS-2 aimed to test the efficacy of a 6-week open-label induction treatment with oral budesonide (1 mg, twice daily)…